Annovis Bio
News
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Buy" by Analysts
Ticker Report Shares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have received a consensus recommendation of "Buy" from the six brokerages that are covering the company, Marketbeat reports. One investment...\n more…
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN Annovis Bio Inc. (NYSE: ANVS) ( Annovis or the Company ), a late-stage clinical drug platform company developing novel therapies for...\n more…
Annovis Bio, Inc.'s (NYSE:ANVS) market cap rose US$24m last week; individual investors who hold 56% profited and so did insiders
Simply Wall St Key Insights Annovis Bio's significant individual investors ownership suggests that the key decisions are influenced by...\n more…
Annovis Bio (ANVS) Receives a Hold from Maxim Group
TipRanks Financial Blog In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Annovis Bio (ANVS - Research Report). The company's sha...\n more…
